
Lantern Pharma Inc is a biotechnology business based in the US. Lantern Pharma shares (LTRN) are listed on the NASDAQ and all prices are listed in US Dollars. Lantern Pharma employs 14 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Lantern Pharma
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LTRN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Active traders

Lantern Pharma stock price (NASDAQ: LTRN)
Use our graph to track the performance of LTRN stocks over time.Lantern Pharma shares at a glance
Latest market close | $5.64 |
---|---|
52-week range | $4.76 - $15.00 |
50-day moving average | $5.72 |
200-day moving average | $7.54 |
Wall St. target price | $31.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.26 |
Buy Lantern Pharma shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Lantern Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lantern Pharma price performance over time
Historical closes compared with the close of $5.64 from 2022-07-06
1 week (2022-06-30) | -1.23% |
---|---|
1 month (2022-06-07) | -1.05% |
3 months (2022-04-05) | -21.23% |
6 months (2022-01-03) | N/A |
1 year (2021-07-07) | -59.42% |
---|---|
2 years (2020-07-07) | -56.88% |
3 years (2019-07-03) | N/A |
5 years (2017-07-03) | N/A |
Lantern Pharma financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -11.77% |
Return on equity TTM | -19.09% |
Profit margin | 0% |
Book value | $6.03 |
Market capitalisation | $61.8 million |
TTM: trailing 12 months
Lantern Pharma share dividends
We're not expecting Lantern Pharma to pay a dividend over the next 12 months.
Lantern Pharma share price volatility
Over the last 12 months, Lantern Pharma's shares have ranged in value from as little as $4.76 up to $15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantern Pharma's is 1.5787. This would suggest that Lantern Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lantern Pharma overview
Lantern Pharma Inc. , a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.
Frequently asked questions
What percentage of Lantern Pharma is owned by insiders or institutions?Currently 18.702% of Lantern Pharma shares are held by insiders and 30.703% by institutions. How many people work for Lantern Pharma?
Latest data suggests 14 work at Lantern Pharma. When does the fiscal year end for Lantern Pharma?
Lantern Pharma's fiscal year ends in December. Where is Lantern Pharma based?
Lantern Pharma's address is: 1920 McKinney Avenue, Dallas, TX, United States, 75201 What is Lantern Pharma's ISIN number?
Lantern Pharma's international securities identification number is: US51654W1018
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert